Anna Morrison

Anna Morrison

Managing Director, Private Markets

Anna kwam in 2020 bij het bfinance Private Markets team als Managing Director met verantwoordelijkheid voor Private Equity onderzoek. Ze heeft uitgebreide ervaring in het investeren en beheren van wereldwijde private equity programma's voor institutionele beleggers, waaronder onderzoek en due diligence in verschillende strategieën en regio's. Voordat ze bij bfinance kwam, was ze Investment Director bij IFM Investors, waar ze meer dan 19 jaar werkte vanuit Australië en vervolgens het Verenigd Koninkrijk. Ze heeft meer dan 10 adviesraden bekleed met private equity programma's variërend van $180m tot c.$1bn.


More insights from the team:

The question of how to integrate private market investments into strategic asset allocation models represents one of the most significant and sensitive issues that allocators face today. This report...

Liquidity-friendly vehicles for illiquid asset classes are on the rise. In order to avoid potential pitfalls, however, it is crucial to interrogate asset managers’ approaches. As part of our...

bfinance’s quarterly report in February 2025: read the team’s latest insights on institutional investor activity, risk appetite, market developments and asset manager performance across all major...

The ‘Impact Private Debt’ sector has undergone a significant phase of expansion during the past two years. This report presents an overview of currently available strategies, while an illustrative...

‘Energy transition’ tailwinds should, it is often argued, boost the prices of particular commodities in the years ahead.

A new survey of more than 300 investors (Global Asset Owner Survey, November 2024) indicates that more than 40% believe ‘like-for-like’ fees for Private Equity managers have decreased in the past...

A secular macroeconomic transition has created an unenviable series of choices—and potential traps— for pension funds, insurers, endowments, foundations, family offices and other ‘asset owners’...

Private debt investors are eyeing apparently superior returns in healthcare lending, with funds’ net IRR targets suggesting a premium of more than 300bps versus conventional direct lending...